Peloton Therapeutics, Inc., a Dallas, TX-based drug discovery and development company, raised an additional $22.2m in Series D funding.
This adds to the earlier Series D close of $52.4m, bringing the full amount raised in the Series D financing round to $74.6m.
Led by John A. Josey, Ph.D., Chief Executive Officer, and Michael F. Haller, Ph.D., Chief Business Officer, Peloton Therapeutics is a clinical-stage biotechnology company that discovers and develops novel small molecule cancer therapies targeting unexploited molecular vulnerabilities. Its lead programs are small molecule inhibitors targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other cancers.